Lymphadenectomy for gastric cancer: Still a matter of debate?

Annali Italiani di Chirurgia

Volumn 83, Issue 3, 2012, Pages 199-207

  Doglietto, Giovanni Battista ^a   Rosa, Fausto ^a   Bossola, Maurizio ^a   Pacelli, Fabio ^a  

^a FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

Author keywords

Gastric cancer; Lymphadenectomy; Surgery

Indexed keywords

EID: 84866167749     PISSN: 2239253X     EISSN: 2239253X     Source Type: Journal    
DOI: None     Document Type: Article

References (68)

1. Hartgrink HH, Van de Velde CJH Status of extended lymph node dissection: Locoregional control is the only way to survive gastric cancer. J Surg Oncol, 2005; 90: 153-65.
2. Bozzetti F, Marubini E, Bonfanti G, et al.: Subtotal versus total gastrectomy for gastric cancer: Five-year survival rates in a multicenter randomised Italian trial. Ann Surg, 1999; 230: 170-78.
3. Gouzi JL, Huguier M, Fagniez PL, et al.: Total versus subtotal gastrectomy for adenocarcinoma of the gastric antrum. Ann Surg, 1989; 209:162-66.
4. Morgagni P, Garcea D, Marrelli D, et al.: Resection line involvement after gastric cancer surgery: Clinical outcome in nonsurgically retreated patients. World J Surg, 2008; 32: 2661-667.
5. Smith DD, Schwarz RR, Schwarz RE Impact of total lymph node count on staging and survival after gastrectomy for gastric cancer: Data from a large US-population database. J Clin Oncol, 2005; 23: 7114-124.
6. Kajitani T Japanese Research Society for the Study of Gastric Cancer: The general rules for gastric cancer study in surgery and pathology. Jap J Surg, 1981; 11:127-45.
7. American Joint Committee on Cancer. In: Beahrs OH, Henson DE, Hutter RVP, Kennedy BJ, (eds): Manual for staging of cancer, 4th edn. Philadelpia: Lippincott Co, 1992.
8. International Union Against Cancer. In: Hermanek P, Sobin LH (eds): TNM classification of malignant tumors, 4th edn., 2nd revision. Berlin-Heidelberg-New York: Springer; 1992.
9. Macintyre IMC, Akoh JA Improving survival in gastric cancer: Review of operative mortality in English language publications from 1970. Br J Surg, 1991; 78:771-76.
10. Akoh JA, Macintyre IMC Improving survival in gastric cancer: Review of 5-year survival rates in English language publications from 1970. Br J Surg, 1992; 79:293-99.
11. Wanebo HJ, Kennedy BJ, Chmiel J, et al.: Cancer of the stomach. A patients care study by the American College of Surgeons. Ann Surg, 1993; 218:583-92.
12. Soga J, Kobayashi K, Saito J, et al.: The role of lymphadenectomy in curative surgery for gastric cancer. World J Surg, 1979; 3:701-8.
13. Kinoshita T, Maruyama K, Sasako M, et al.: Treatment results of gastric cancer patients: Japanese experience. In: Nishi M, Ichakawa H, Nakajima T, Maruyama K, Tahara E (eds): Gastric cancer. Tokyo, Berlin, Heidelberg: Springer-Verlag; 1993:319-30.
14. Sasako M, Sano T, Yamamoto S, et al.: D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med, 2008; 31: 453-62.
15. Maruyama K, Gunven P, Okabayashi K, et al.: Lymph node metastases of gastric cancer. General pattern in 1,931 patients. Ann Surg. 1989; 210:596-602.
16. Cuschieri A: Recent advances in gastrointestinal malignancy. Ann Chir Gynaecol, 1989; 78:228-37.
17. Bonenkamp JJ, van de Velde CJH, Kampschöer GHM, et al. Comparison of factors influencing the prognosis of Japanese, German, and Dutch Gastric cancer patients. World J Surg, 1993; 17:410-15.
18. Bonenkamp JJ, Sasako M, Hermans J, et al.: Extended lymphnode dissection for gastric cancer. N Engl J Med, 1999; 340:908-14.
19. Nashimoto A, Nakajima T, Furukawa H, et al.: Randomised trial of adjuvant chemotherapy with mitomycin, fluorouracil, and cytosine arabinoside followed by oral fluorouracil in serosanegative gastric cancer: Japan clinical oncology group 9206-9201. J Clin Oncol, 2003; 21:2282-287.
20. Wanebo HJ, Kennedy BJ, Winchester DP, et al.: Gastric carcinoma: Does lymph node dissection alter survival? J Am Coll Surg, 1996; 183:616-24.
21. De Manzoni G, Verlato G, Guglielmi A, et al.: Prognostic significance of lymph node dissection in gastric cancer. Br J Surg, 1996; 83:1604-607.
22. Bösing NM, Goretzki PE, Röher HD Gastric cancer: Which patients benefit from systematic lymphadenectomy? Eur J Surg Oncol, 2000; 26:498-505
23. Pacelli F, Doglietto GB, Bellantone R, Alfieri S, Sgadari A, Crucitti F Extensive versus limited lymph node dissection for gastric cancer: A comparative study of 320 patients. Br J Surg, 1993; 80(9):1153-156.
24. Doglietto GB, Pacelli F, Caprino P, Bossola M, Di Stasi C Pancreas-preserving total gastrectomy for gastric cancer. Arch Surg, 2000; 135(1):89-94.
25. Doglietto GB, Pacelli F, Caprino P, Papa V Role of lymphadenectomy in gastric carcinoma. Ann Ital Chir, 2001; 72: 39-46.
26. Crucitti F, Doglietto GB, Bellantone R, Pacelli F, Perri V, Tommasini O, Genovese V Importance of node excision in the surgical treatment of gastric carcinoma. Ann Ital Chir, 1989; 60: 477-82.
27. Dent DM, Madden MV, Price SK Randomized comparison of R1 and R2 gastrectomy for gastric carcinoma. Br J Surg, 1988; 75:110-12.
28. Robertson CS, Chung SCS, Woods SDS, et al.: A prospective randomized trial comparing R1 subtotal gastrectomy with R3 total gastrectomy for antral cancer. Ann Surg, 1994; 220:176-82.
29. Hartgrink HH, van de Velde CJH, Putter H, et al. Extended lymph node dissection for gastric cancer: Who may benefit? Final results of the randomised Dutch Gastric Cancer Group Trial. J Clin Oncol, 2004; 22:2069-77.
30. Bonenkamp JJ, Sasako M, Hermans J, et al.: Extended lymphnode dissection for gastric cancer. N Engl J Med, 1999; 340:908-14.
31. Mansfield PF Lymphadenectomy for gastric cancer. J Clin Oncol 2004; 22:2759-761.
32. Jansen EP, Boot H, Verheij M, et al.:Optimal locoregional treatment in gastric cancer. J Clin Oncol, 2005; 23:4509-517.
33. van de Velde CJ, Peeters KC The gastric cancer treatment controversy. J Clin Oncol, 2003; 21:2234-236.
34. Douglass HO, Jr., Hundahl SA, Macdonald JS, Khatri VP Gastric cancer: D2 dissection or low Maruyama Index-based surgery. A debate. Surg Oncol Clin N Am, 2007; 16(1):133-55.
35. Khatri VP, Douglass HO, Jr D2.5 dissection for gastric carcinoma. Arch Surg, 2004; 139(6):662-69.
36. Degiuli M, Sasako M, Ponti A, et al.: Survival results of a multicentre phase II study to evaluate D2 gastrectomy for gastric cancer. Br J Cancer, 2004; 90: 1727-732.
37. Degiuli M, Sasako M, Calgaro M, et al.: Morbidity and mortality after D1 and D2 gastrectomy for cancer: Interim analysis of the Italian Gastric Cancer Study Group randomised surgical trial. Eur J Surg Oncol, 2004; 30:303-38.
38. Degiuli M, Sasako M, Ponti A Morbidity and mortality in the Italian Gastric Cancer Study Group randomized clinical trial of D1 versus D2 resection for gastric cancer. Br J Surg, 2010; 97:643-49.
39. Wu CW, Hsiung CA, Lo SS, et al.: Nodal dissection for patients with gastric cancer: A randomised controlled trial. Lancet Oncol, 2006; 7:309-15.
40. Sasako MM, Sano T, Yamamoto, et al. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med, 2008; 359:453-62.
41. McCulloch P, Nita ME, Kazi H, et al.: Extended versus limited lymph node dissection technique for adenocarcinoma of the stomach (Cochrane Review). The Cochrane Library. Chichester, UK: Wiley, 2003.
42. Enzinger PC, Benedetti JK, Meyerhardt JA, et al.: Impact of hospital volume on recurrence and survival after surgery for gastric cancer. Ann Surg, 2007; 245(3):426-34.
43. Schwarz RE, Smith DD Clinical impact of lymphadenectomy extent in resectable gastric cancer of advanced stage. Ann Surg Onco,l 2007; 14(2):317-28.
44. Siewert JR, Bittcher K, Stein HJ, et al. Relevant prognostic factors in gastric cancer: Ten-year results of the German Gastric cancer Study. Ann Surg, 1998; 228:449-61.
45. Nitti D, Marchet A, Olivieri M, et al.: Ratio between metastatic and examined lymph nodes is an independent prognostic factor after D2 resection for gastric cancer: Analysis of a large European monoinstitutional experience. Ann Surg Oncol, 2003; 10:1077-85.
46. Inoue K, Nakane Y, Iiyama H, et al.: The superiority of ratiobased lymph node staging in gastric carcinoma. Ann Surg Oncol, 2002; 9:27-34.
47. American Joint Committee on Cancer: AJCC Cancer Staging Atlas. Springer Science. New York:Business Media Inc, 2006.
48. Bunt AM, Hermans J, Smith VT, et al.: Surgical/pathologic stage migration confounds comparisons of gastric cancer survival rates between Japan and Western countries. J Clin Oncol, 1995; 13:19-25.
49. Macdonald JS, Smalley SR, Benedetti J, et al.: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med, 2001; 345:725-30.
50. Mullaney PJ, Wadley MS, Hyde C, et al.: Appraisal of compliance with the UICC/AJCC staging system in the staging of gastric cancer. Union Internacional Contra la Cancrum/American Joint Committee on Cancer. Br J Surg, 2002; 89:1405-408.
51. Marchet A, Mocellin S, Ambrosi A, Morgagni P The ratio between metastatic and examined lymph nodes (N Ratio) is an independent prognostic factor in gastric cancer regardless of the type of lymphadenectomy. Results from an Italian multicentric study in 1853 patients. Ann Surg, 2007; 245:543-52.
52. Bando E, Yonemura Y, Taniguchi K, et al. Outcome of ratio of lymph node metastasis in gastric carcinoma. Ann Surg Oncol, 2002; 9:775-84.
53. Celen O, Yildirim E, Berberoglu U Prognostic impact of positive lymph node ratio in gastric carcinoma. J Surg Oncol, 2007; 96:95-101.
54. Kitagawa Y, Fujii H, Mukai M, et al.: The role of the sentinel lymph node in gastrointestinal cancer. Surg Clin North Am, 2000; 80:1799-809.
55. Ryu KW, Lee JH, Kim HS, et al.: Prediction of lymph nodes metastasis by sentinel node biopsy in gastric cancer. Eur J Surg Oncol, 2003; 29:895-99.
56. Orsenigo E, Tomajer V, Di Palo S, et al. Sentinel node mapping during laparoscopic distal gastrectomy for gastric cancer. Surg Endosc, 2008; 22:118-21.
57. Kitagawa Y, Fujii H, Kumai K, et al.: Recent advances in sentinel node navigation for gastric cancer: A paradigm shift of surgical management. J Surg Oncol, 2005; 90:147-51, discussion 151-52.
58. Lim RB, Wong JH Sentinel lymphadenectomy in gynecologic and solid malignancies other than melanoma and breast cancer. Surg Clin North Am, 2000; 80:1787-798.
59. Seto Y, Nagawa H, Muto T Impact of lymph node metastasis on survival with early gastric cancer. World J Surg, 1997; 21:186-89, discussion 190.
60. Coburn NG, Swallow CJ, Kiss A, et al.: Significant regional variation in adequacy of lymph node assessment and survival in gastric cancer. Cancer, 2006; 107:2143-151.
61. Lordick F, Siewert JR Recent advances in multimodal treatment for gastric cancer: A review. Gastric Cancer, 2005; 8:78-85.
62. Kim S, Lim DH, Lee J, et al.: An observational study suggesting clinical benefit for adjuvant post-operative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach. Int J Radiat Oncol Biol Phys, 2005; 63:1279-285.
63. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med, 2006; 355:11-20.
64. Sakuramoto S, Sasako M, Yamaguchi T, et al.:Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007; 357:1810-820.
65. Cho BC, Jeung HC, Choi HJ, et al.: Prognostic impact of resection margin involvement after extended (D2/D3) gastrectomy for advanced gastric cancer: A 15-year experience at a single institute. J Surg Oncol, 2007; 95:461-68.
66. Lim H, Karpeh MS, Klimstra DS, et al.:Effect of microscopic resection line disease on gastric cancer survival. J Gastrointest Surg, 1999; 3:24-33.
67. Martin RC II, Jaques DP, Brennan MF, et al.: Achieving RO resection for locally advanced gastric cancer: Is it worth the risk of multiorgan resection? J Am Coll Surg, 2002; 194:568-77.
68. Martin RC II, Jaques DP, Brennan MF, et al.: Extended local resection for advanced gastric cancer: Increased survival versus increased morbidity. Ann Surg, 2002; 236:159-65.